Researchers discovered that a protein called ANGPTL6 may help prevent liver scarring (fibrosis), a serious condition that develops when the liver gets damaged and inflamed. Using mouse models and lab studies, scientists found that when they increased ANGPTL6 levels, it reduced liver damage and inflammation caused by an unhealthy diet. The protein works by blocking a specific pathway that normally triggers liver cells to become scarred. While these results are promising, the research is still in early stages and more studies are needed before this could become a treatment for people with liver disease.
The Quick Take
- What they studied: Whether a protein called ANGPTL6 can prevent or reduce liver scarring by blocking the biological signals that cause scarring to happen
- Who participated: Laboratory mice fed a special diet designed to damage their livers, plus human liver cells grown in dishes. The exact number of mice wasn’t specified in the abstract.
- Key finding: When researchers increased ANGPTL6 levels in mice, the mice developed significantly less liver scarring and had lower markers of liver damage compared to mice without extra ANGPTL6
- What it means for you: This research suggests ANGPTL6 could potentially become a new treatment for liver scarring diseases, but it’s still in early research stages. People with liver disease should not expect this as a treatment option yet, and should continue following their doctor’s current recommendations.
The Research Details
This was a laboratory research study using two main approaches. First, researchers created mice with liver damage by feeding them a special diet lacking certain nutrients (methionine and choline). They then used a technique to increase ANGPTL6 protein levels in these mice’s livers and measured whether this reduced scarring and liver damage.
Second, the researchers used human liver cells grown in laboratory dishes to understand exactly how ANGPTL6 works. They added or removed the ANGPTL6 protein and watched how it affected the cells’ behavior and the biological signals involved in scarring.
The researchers measured liver damage using blood tests (looking for liver enzymes), examined liver tissue under a microscope, and used molecular techniques to measure specific proteins and genes involved in scarring.
This research approach is important because it combines whole-animal studies (which show how something works in a living body) with cell studies (which show the exact biological mechanisms). This combination helps researchers understand not just whether something works, but how and why it works, which is crucial for developing new treatments.
This study was published in a peer-reviewed scientific journal, meaning other experts reviewed it before publication. The researchers used multiple methods to measure their results, which increases confidence in the findings. However, the study was conducted entirely in mice and lab cells, not in humans, so results may not directly apply to people. The abstract doesn’t specify the exact number of mice used, which makes it harder to evaluate the study’s statistical power.
What the Results Show
When researchers increased ANGPTL6 levels in mice with liver damage, several positive changes occurred. The mice showed reduced liver scarring compared to control mice, and their blood tests showed lower levels of liver enzymes (ALT and AST), which indicate less liver damage. The livers also showed less inflammation and fewer markers of fibrosis (scarring).
The researchers then did a follow-up experiment to understand how ANGPTL6 works. They found that ANGPTL6 appears to work by blocking a specific biological pathway called TGF-β1/Smad3, which is known to trigger the scarring process. When they artificially reactivated this pathway, the protective effects of ANGPTL6 disappeared, confirming this is how the protein works.
In human liver cells grown in dishes, ANGPTL6 successfully prevented the cells from becoming activated (a step that leads to scarring). This effect was blocked when researchers added back the TGF-β1/Smad3 pathway, further confirming the mechanism.
The study found that ANGPTL6 levels were naturally lower in livers that already had scarring, suggesting the body may lose this protective protein as liver disease develops. This finding suggests that restoring ANGPTL6 levels might help reverse or prevent progression of existing liver disease. The researchers also found that blocking the TGF-β1/Smad3 pathway enhanced ANGPTL6’s protective effects, suggesting combination treatments might be more effective than ANGPTL6 alone.
This research builds on previous knowledge that the TGF-β1/Smad3 pathway is a key driver of liver scarring. However, this is one of the first studies to identify ANGPTL6 as a natural suppressor of this pathway. Previous research has shown that ANGPTL6 is involved in metabolism and is produced by liver cells, but its role in preventing scarring was previously unknown. This study fills an important gap in understanding how the body naturally protects itself from liver scarring.
The most significant limitation is that all experiments were conducted in mice and laboratory cells, not in humans. Mice don’t always respond to treatments the same way humans do, so results may not directly translate to human medicine. The study used a specific type of liver damage (from a nutrient-deficient diet) that may not perfectly match all types of human liver disease. Additionally, the abstract doesn’t provide specific sample sizes for the mouse studies, making it difficult to assess whether the results are statistically robust. Long-term effects and potential side effects of increasing ANGPTL6 were not studied.
The Bottom Line
Based on this research alone, there are no new recommendations for the general public. This is early-stage research that has not yet been tested in humans. People with liver disease should continue following their doctor’s current treatment recommendations, which may include lifestyle changes (diet, exercise, limiting alcohol) and medications as prescribed. Future human studies would be needed before ANGPTL6-based treatments could be considered for patient use.
This research is most relevant to people with liver scarring (fibrosis) or metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH), as well as researchers developing new liver disease treatments. People with fatty liver disease, hepatitis, or other chronic liver conditions may eventually benefit if this research leads to new treatments. However, this research should not influence current treatment decisions for anyone with liver disease.
This research is in very early stages. If ANGPTL6-based treatments prove safe and effective in human studies (which haven’t started yet), it would typically take 10-15 years before such a treatment could become available to patients. People should not expect this as a treatment option in the near future.
Want to Apply This Research?
- Users with liver disease could track liver health markers they monitor with their doctor, such as ALT and AST enzyme levels from blood tests, along with ultrasound or imaging results showing liver scarring progression. This creates a baseline for comparing against future treatments.
- Users could use the app to track lifestyle factors that protect liver health: daily alcohol consumption (aiming for none or minimal), weekly exercise minutes, and adherence to a balanced diet low in processed foods. These evidence-based behaviors support liver health while waiting for new treatments to be developed.
- Set up quarterly reminders to log liver function test results from doctor visits. Track trends in enzyme levels and imaging findings over time. This long-term monitoring helps users and their doctors assess disease progression and treatment effectiveness as new therapies become available.
This research describes early-stage laboratory findings in mice and human cells, not proven treatments for people. These results have not been tested in human patients and should not influence current medical treatment decisions. If you have liver disease or concerns about liver health, consult with your doctor about evidence-based treatment options. Do not attempt to increase ANGPTL6 levels or change treatments based on this research without medical supervision. This summary is for educational purposes only and does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.